CN1638779A - 磷脂酰丝氨酸在治疗注意力缺乏综合症(adhs)中的应用 - Google Patents
磷脂酰丝氨酸在治疗注意力缺乏综合症(adhs)中的应用 Download PDFInfo
- Publication number
- CN1638779A CN1638779A CNA028215648A CN02821564A CN1638779A CN 1638779 A CN1638779 A CN 1638779A CN A028215648 A CNA028215648 A CN A028215648A CN 02821564 A CN02821564 A CN 02821564A CN 1638779 A CN1638779 A CN 1638779A
- Authority
- CN
- China
- Prior art keywords
- phosphatidylserine
- application
- dosage
- day
- adhs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 title claims abstract description 67
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 title claims abstract description 67
- 238000011282 treatment Methods 0.000 title claims abstract description 25
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 20
- 101710155073 2-amino-3,7-dideoxy-D-threo-hept-6-ulosonate synthase Proteins 0.000 title claims abstract 6
- 230000006735 deficit Effects 0.000 title abstract 2
- 239000000654 additive Substances 0.000 claims abstract description 21
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 12
- 150000001413 amino acids Chemical class 0.000 claims abstract description 10
- 235000004626 essential fatty acids Nutrition 0.000 claims abstract description 9
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 6
- 239000011707 mineral Substances 0.000 claims abstract description 6
- 239000007787 solid Substances 0.000 claims abstract description 4
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 3
- 230000003203 everyday effect Effects 0.000 claims description 25
- 230000000996 additive effect Effects 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 14
- 230000007812 deficiency Effects 0.000 claims description 13
- 230000002949 hemolytic effect Effects 0.000 claims description 12
- 229940024606 amino acid Drugs 0.000 claims description 9
- 235000001014 amino acid Nutrition 0.000 claims description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- 235000006708 antioxidants Nutrition 0.000 claims description 7
- 230000008451 emotion Effects 0.000 claims description 7
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- DVSZKTAMJJTWFG-UHFFFAOYSA-N docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC=CC(O)=O DVSZKTAMJJTWFG-UHFFFAOYSA-N 0.000 claims description 6
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 235000013373 food additive Nutrition 0.000 claims description 5
- 239000002778 food additive Substances 0.000 claims description 5
- 230000035479 physiological effects, processes and functions Effects 0.000 claims description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 4
- 229930003268 Vitamin C Natural products 0.000 claims description 4
- 229930003427 Vitamin E Natural products 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000013355 food flavoring agent Nutrition 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 4
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims description 4
- 235000010755 mineral Nutrition 0.000 claims description 4
- 235000019154 vitamin C Nutrition 0.000 claims description 4
- 239000011718 vitamin C Substances 0.000 claims description 4
- 235000019165 vitamin E Nutrition 0.000 claims description 4
- 229940046009 vitamin E Drugs 0.000 claims description 4
- 239000011709 vitamin E Substances 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- 235000016787 Piper methysticum Nutrition 0.000 claims description 3
- 240000005546 Piper methysticum Species 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 235000020664 gamma-linolenic acid Nutrition 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 239000002858 neurotransmitter agent Substances 0.000 claims description 3
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 2
- 229910004298 SiO 2 Inorganic materials 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 230000002421 anti-septic effect Effects 0.000 claims description 2
- 229940093797 bioflavonoids Drugs 0.000 claims description 2
- 235000014633 carbohydrates Nutrition 0.000 claims description 2
- 235000021466 carotenoid Nutrition 0.000 claims description 2
- 150000001747 carotenoids Chemical class 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 229960003624 creatine Drugs 0.000 claims description 2
- 239000006046 creatine Substances 0.000 claims description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 2
- 235000020776 essential amino acid Nutrition 0.000 claims description 2
- 239000003797 essential amino acid Substances 0.000 claims description 2
- 235000019441 ethanol Nutrition 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 235000019136 lipoic acid Nutrition 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 2
- 229940012843 omega-3 fatty acid Drugs 0.000 claims description 2
- 235000020665 omega-6 fatty acid Nutrition 0.000 claims description 2
- 229940033080 omega-6 fatty acid Drugs 0.000 claims description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 2
- 229940067626 phosphatidylinositols Drugs 0.000 claims description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 235000000346 sugar Nutrition 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 229960002663 thioctic acid Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 125000000837 carbohydrate group Chemical group 0.000 claims 1
- 235000013376 functional food Nutrition 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 3
- 239000000935 antidepressant agent Substances 0.000 abstract description 2
- 229940005513 antidepressants Drugs 0.000 abstract description 2
- 230000008092 positive effect Effects 0.000 abstract description 2
- 239000013589 supplement Substances 0.000 abstract description 2
- ZPDQFUYPBVXUKS-YADHBBJMSA-N 1-stearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COP(O)(=O)OC[C@H](N)C(O)=O ZPDQFUYPBVXUKS-YADHBBJMSA-N 0.000 abstract 1
- 230000037213 diet Effects 0.000 abstract 1
- 235000005911 diet Nutrition 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 230000009469 supplementation Effects 0.000 abstract 1
- 230000003935 attention Effects 0.000 description 20
- 208000024891 symptom Diseases 0.000 description 12
- 230000000694 effects Effects 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 8
- 206010020651 Hyperkinesia Diseases 0.000 description 7
- 208000000269 Hyperkinesis Diseases 0.000 description 7
- 230000006872 improvement Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000015654 memory Effects 0.000 description 4
- 206010012335 Dependence Diseases 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 238000013456 study Methods 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 208000030990 Impulse-control disease Diseases 0.000 description 2
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 2
- 206010029216 Nervousness Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- -1 bioflavonoids Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229960002887 deanol Drugs 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 230000007087 memory ability Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000008447 perception Effects 0.000 description 2
- 150000008106 phosphatidylserines Chemical class 0.000 description 2
- 229960001153 serine Drugs 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 208000017194 Affective disease Diseases 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010057315 Daydreaming Diseases 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 206010013486 Distractibility Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000020358 Learning disease Diseases 0.000 description 1
- 206010027374 Mental impairment Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000012761 aggressive behavior Diseases 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 208000024823 antisocial personality disease Diseases 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000550 effect on aging Effects 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 235000014058 juice drink Nutrition 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 231100000863 loss of memory Toxicity 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000019449 other food additives Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000010332 selective attention Effects 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000002438 stress hormone Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000003936 working memory Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Botany (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及磷脂酰丝氨酸(PS)，溶血磷脂酰丝氨酸或/和其生理上可接受的盐，以每日小剂量长期治疗和较高剂量短期治疗，同时与适当的选自抗氧化剂、必需脂肪酸、矿物质、氨基酸、情绪提高剂或/和磷脂的添加剂联合，在治疗注意力缺乏综合症(ADHS)中的应用。就此而言，优选给予2至20岁的受试者，更优选给予3至10岁的受试者，其中磷脂酰丝氨酸和添加剂以固体或液体制剂形式使用。由于磷脂酰丝氨酸的良好特性，它特别适合作为与ADHS有关疾病的治疗剂或食品添加剂。也应该强调的是，磷脂酰丝氨酸即使高剂量和较长补充时期使用也有良好的耐受性，以及其突出的顺应性。
Description
本发明涉及磷脂酰丝氨酸、溶血磷脂酰丝氨酸或/和其生理上可接受的盐，以及磷脂酰丝氨酸、溶血磷脂酰丝氨酸或/和其生理上可接受的盐结合添加剂，在治疗注意力缺乏综合症(ADHS)中的应用。
注意力缺乏综合症(ADHS；注意力缺乏/多动症)应理解为一种临床综合症，其特征为：集中能力和长时间保持注意的能力的相当大的损害，冲动控制障碍，以及任意的运动过度和不安。过去，这种综合症也被称作“运动机能亢进综合症”或“轻微脑功能紊乱”。
ADHS的临床现象与神经生物学定义的脑代谢和神经递质的改变有关，因而主要涉及神经学临床现象，其可以导致严重的心理后果(Swanson JM，Sergeant JA，Taylor E，Sonuga-Barke EJ，Jensen PS，Cantwell DP，注意力缺乏多动症和运动机能亢进症，Lancet 1998；351：429-33)。
根据最近的研究，将过去的几年中，没有运动过度征象的特殊的注意力缺乏综合症划分为所谓的“注意力不集中型”(Lahey BB；CarlsonCL，没有多动的注意力缺乏障碍的诊断类别的有效性：关于学习障碍的文献、杂志的综述，1991；24：110-120)。对于不再能检测到所有的典型儿童期症状的成年病例，在现在的DSM(精神障碍的诊断和统计手册)类别中提出了附加的名称“部分免除”或“运动机能亢进综合症剩余类型”。
尽管所谓的多动综合症或运动机能亢进综合症是儿童和青少年中最频繁发生的精神病学障碍之一，但在德国，很大程度上仍没有成年人注意力缺乏综合症症状的描述。对这些儿童病程的持续研究显示：与进攻性行为障碍的发生和反社会人格障碍，成瘾症和情感障碍有关的严重损害仍持续到成年期(Mannuzza S，Klein RG，Bessler A，Malloy P，LaPadula M，多动男孩的成年结局，Arch General Psychiatry 1993；50：565-76)。
如今ADHS占人口中的比例，估计在小学为3-4％，青少年为2％。估计所有儿童、青少年和成年人患ADHS的比例为2-10％。与症状在成年期消失的观点相反，仍确定高达60％的正式患病的儿童在青少年期有相当程度的损伤。
ADHS通常首先涉及纯粹的生物学易患病的体质，但依赖个人生活的环境和紧张程度会产生非常不同的结果。
根据现在的研究，在对于患者的单纯的焦虑症或冲动、反社会、歇斯底里地行为古怪或抑郁的典型症状的临床现象之外，至少必须进行额外的对持续到成年期的运动机能亢进综合症的诊断。
作为注意力缺乏综合症的基本病症，选择性注意力障碍是典型的，其中患者大多没有注意力不集中，但试图同时遵循内心和外在的感觉或想法。总之这些患者的自我控制能力受到严重障碍，由此在减少抑制的情形下导致在失眠、情绪调节、认知功能、记忆和行为计划方面的基本行为功能的丧失。
通常人们即使从事不愉快或令人厌烦的工作时，如果能够预期有一些积极的结果，他们也会产生某种动力和耐力。患ADHS症的人们则相反：必需首先刺激或激活，才能开始运作。
在ADHS的情形下抑制功能降低的临床结果是：一方面过度兴奋或高度敏感和冲动控制障碍，也表现为注意力分散加剧或注意力降低，以及集中能力降低。
根据目前有效的诊断标准，ADHS的症状应该在7岁前已经显现。
ADHS患儿通常在儿童阶段就已经出现轻微异常、如行走或说话方面的发育延迟或感知障碍或协调运动功能障碍。也被描述为以精细神经学特点(如肌肉张力偏离或反射和感觉的不对称)的形式存在的所谓的“温和征象”。除了别的以外，这种征象导致书写时明显的牢固的压摁或紧张，致使笔迹差。7岁后尿床也特别频繁地发生。
根据P.H.Wender(成年人注意力缺乏多动障碍，OxfordUniversity Press，1995)将儿童多动综合症总结如下：
·多动或不安静高于平均程度的儿童，神经质，喋喋不休，烦燥。
·注意力缺乏或注意力范围减少，容易不集中。
·患病儿童不能达到被认为能够达到的全部成绩潜力。
·“只要他/她想，他/她就能”。遗忘性，在系列任务和遵循指示和完成任务方面的问题。
在成年期，作为重要症状，不能达到所有自己确立的目的的感觉或明显能力差的感觉经常占最显著的位置。ADHS成年期的典型症状如认知异常，持久注意范围改变，工作记忆障碍，过度敏感和冲动，对压力和冲动的承受力低，以及成瘾行为或如“肾上腺素反冲”形式的高度刺激，“经典”的多动和无放松能力。
磷脂酰丝氨酸类物质为天然存在于人体中，以前被归于溶血卵磷脂一类的磷脂。
磷脂酰丝氨酸支持人体细胞的大量功能，在脑内出现自然升高的浓度，它支持神经细胞及其与之相联系的细胞的极其敏感的功能。磷脂酰丝氨酸是经充分研究的物质，它为整个生命阶段中生物的幸福和健康作出贡献。最重要的是，它有所谓的抗衰老效果。磷脂酰丝氨酸起抗压力作用，有抗抑郁效果，甚至在某种程度上，有返老还童的作用。由于提高记忆力的能力，抗抑郁作用和降低血中应激激素的能力，磷脂酰丝氨酸成为大脑所有营养物质中最重要的。
如同其它磷脂一样，磷脂酰丝氨酸作为食品添加剂，不仅以直接的方式，对健康产生有益的作用。磷脂酰丝氨酸能均衡地改善大量其它食品或食品添加剂的吸收，或与它们产生协同作用。这已经在临床双盲研究中得到证实。
作为一种磷脂，磷脂酰丝氨酸是细胞膜的重要成分。这些含磷脂成分的非常稀薄柔软的三维结构是调节或保持细胞能量平衡以确保身体细胞协调工作的酶系统的重要基质。
此外，已知磷脂酰丝氨酸产生能量以支持大脑，它积极影响细胞/细胞连接(神经原的神经线连接)，它增强如乙酰胆碱、多巴胺、去甲肾上腺素和5-羟色胺的化学递质的作用，能导致如集中、学习能力、短期记忆和词汇记忆这样的大脑认知能力的改善。
磷脂酰丝氨酸也是抗大脑衰老过程的重要活性物质，这已经被约18项双盲研究和40多种已发表的人类研究所证实。而且，也据说磷脂酰丝氨酸有至少部分逆转与衰老过程有关的记忆丧失的能力。
除了其它形式的治疗，药物治疗也被用于治疗ADHS。用磷脂酰丝氨酸治疗ADHS病人的最初尝试在现有技术中已有描述。在这个实验中，首先在2个月的时间里使用每日100mg的小剂量。这种治疗没有导致症状的明显改善。随后，在4个月的时间里使用更高的剂量(每日200至300mg，对症状严重的病例每日高达500mg)。这种高剂量的治疗对3至19岁的典型ADHS症状的27位受试人中的25位有积极的效果。其中一位受试人(7岁，女性)仅有轻微改善，另一位受试人(15岁，女性)不能清楚描述改善(Dr.Parris Kidd，对ADHS明确观点：PS，在第11届食品设计展示会上的演讲，Tokyo Big Sight，Tokyo，Japan，September 20th，2000)。在这个实验中，在给药同时，没有药物副作用发生，但是所用的剂量相当高。
因此，本发明的目的是提供基于磷脂酰丝氨酸的制剂用于治疗注意力缺乏综合症(ADHS)的有效制剂，其在有效剂量下，取得良好的生理耐受性和良好的顺应性而无副作用。
本发明的另一个目的是提供用于治疗ADHS的磷脂酰丝氨酸的给药剂量和持续时间的更有效的剂量形式。
通过磷脂酰丝氨酸、溶血磷脂酰丝氨酸或/和其生理上可接受的盐单独应用或结合添加剂应用来达到所述目的。这里使用的术语磷脂酰丝氨酸(PS)，包含所有包括溶血化合物及其相应盐的属于磷脂酰丝氨酸类物质的化合物。对此的实例是磷脂酰-L-丝氨酸或溶血磷脂酰-L-丝氨酸。
令人惊奇地发现，当用于治疗ADHS时，PS与其它物质取合使用显示协同作用。因此本发明由此涉及磷脂酰丝氨酸(PS)，溶血磷脂酰丝氨酸或/和其生理上可接受的盐与一种添加剂联合在制备用于治疗注意力缺乏综合症(ADHS)的制剂中的应用。这里所用的术语“治疗”包含ADHS的治疗和预防。
根据本发明的PS的应用，一方面能够减少PS的剂量，另一方面能够缩短治疗期。而且，使用根据本发明的磷脂酰丝氨酸的结果是：由于它众所周知的良好耐受性，即使高剂量和长期补充治疗使用也没有任何限制，磷脂酰丝氨酸的顺应性不是问题，并且在ADHS受试者中也没有发生成瘾作用。此外，根据本发明使用的PS比之前已知的药物在更大的程度上显示了它对ADHS的积极效果。
当使用根据本发明的磷脂酰丝氨酸(PS)和一种添加剂的组合物时，证明当磷脂酰丝氨酸的给药剂量为每日20至1000mg，优选50至600mg时才有效。
每日剂量为1至10,000mg，尤其是5至5000mg，特别是50至1000mg适合于添加剂或添加剂的混合物。
在此给药至少7天，优选不多于6个月是适宜的，并且在停止或/和重新调整每日剂量之后各自的补充期容易且完全没有问题地可重复。就此而言，7天的给药期不必连贯。
根据发明的应用，适宜的添加剂包括抗氧化剂、必需脂肪酸、矿物质、氨基酸、情绪提高剂、磷脂或/和其混合物。所述添加剂对于脑功能有积极作用：抗氧化剂尤其保护被集中供氧的组织或器官；必需脂肪酸和磷脂支持和保持细胞膜和特别是脑内的神经细胞或神经组织的功能；矿物质，特别是镁和钙，也在神经元作用中有重要功能。
优选的抗氧化剂如生物类黄酮，维生素E，维生素C，α-硫辛酸或/和类胡萝卜素。ω-3-脂肪酸和ω-6-脂肪酸和特别优选二十二碳六烯酸(DHA)和γ-亚麻酸(GLA)是适宜的必需脂肪酸的实例。适宜的氨基酸如必需氨基酸或/和氨基酸衍生物，如肌酸。镁和钙是优选的矿物质的实例。特别优选金丝桃提取物(Johanniskraut-Extrakte)，Kava-Kava或/和其混合物用作情绪提高剂。优选的磷脂如磷脂酰胆碱(卵磷脂)，磷脂酸，磷脂酰乙醇胺或/和磷脂酰肌醇。
除了磷脂酰丝氨酸(PS)及其适宜的衍生物与添加剂的联合应用，本发明的另一个主题是没有其它的添加剂，只有磷脂酰丝氨酸，溶血磷脂酰丝氨酸或/和其生理上可接受的盐在制备用于治疗注意力缺乏综合症(ADHS)的制剂中的应用。在此，治疗方案是在最多2个月的治疗期中，优选每日剂量是150至600mg或/和在多于2个月，优选多于3个月和特别优选多于4个月的治疗期中，适宜的每日剂量是50至150mg。
在根据本发明的磷脂酰丝氨酸的应用中，令人惊奇地发现：与现有技术相比，长期低剂量和短期较高剂量使用磷脂酰丝氨酸(PS)非常适于ADHS症状的治疗。
根据本发明的磷脂酰丝氨酸的应用也显示出：即使在高剂量和较长补充期使用，它也有良好的顺应性，而且在这种情况下，ADHS病人也没有发生成瘾作用。
这也证明了，当较长期给予磷脂酰丝氨酸(多于2个月)，优选每日剂量为50至150mg和更优选每日剂量100至150mg时非常有利；在不超过2个月的短期给予磷脂酰丝氨酸的情况下，每日剂量为150至600mg和优选250至450mg尤其合适。
因为磷脂酰丝氨酸是自身的物质，一般来说，它代谢非常迅速和完全，而且在非常短的“积聚时间”之后，就已经发挥了它的良好作用。然而，在本发明的具体实施方式中，不是必须连续的7天被认为是用PS治疗ADHS的最短时期。根据本发明，6个月是用于ADHS的磷脂酰丝氨酸规律性服用的上限，但补充阶段在停止或/和调整每日剂量后能容易且完全没有问题地多次重复。
全体受试者证明使用根据本发明的磷脂酰丝氨酸(衍生物)适用于治疗年龄在2和20岁之间的ADHS，尤其为防止此后不能挽回的持续症状和为了毫无疑问的顺应性，证明对年龄在3和10岁之间患者特别合适。
根据本发明在所有具体实施方式中，磷脂酰丝氨酸(PS)，及其适宜的衍生物，溶血磷脂酰丝氨酸或/和其生理上可接受的盐可以以固体和液体制剂的形式用于治疗ADHS。
适宜的固体制剂如粉剂、咀嚼片、含片和泡腾片、糖衣丸和胶囊，以及考虑到一般的低龄优选受试者，糖果或巧克力棒是适用的。汁液和软饮料特别适合作为液体制剂的实施例。
根据本发明的制剂可另外包括生理上可接受的或/和生理上有效的添加剂或/和制剂佐剂。根据本发明应用的适宜的生理上可接受或/和生理上有效的添加剂如抗氧化剂、必需脂肪酸成分、抗抑郁剂(例如：(情绪提高剂，优选植物来源的，如金丝桃或Kava-Kava)、微生态调节剂、各种PS磷脂或天然脑内物质二甲基氨基乙醇(DMAE)以及醇类、糖、维生素、微量元素、氨基酸、神经递质、刺激物、着色剂和调味剂。而且可以使用磷脂酰丝氨酸与能产生附加或协同作用的已知药物或对ADHS有效的其它药物的组合物。如果产生协同作用，能够有利地减少各自有效的PS剂量，并且使各自的每日用量与身高和体重的身体指数相匹配，在儿童和青少年的病例中尤其如此。
根据本发明使用的适宜的制剂佐剂如碳水化合物(例如：甲基纤维素)、SiO2、硬脂酸盐、增溶剂、调味剂、防腐剂和分离剂以及增稠剂(Texturantien)。
由于良好的生理耐受性和对注意力缺乏综合症的显著疗效，本发明范围内的磷脂酰丝氨酸(PS)尤其适用于治疗剂或食品添加剂，尤其在食品添加剂中，可以保持小剂量，也能长期给药。
下列实施例1至4阐明当使用根据本发明的磷脂酰丝氨酸(PS)或磷脂酰丝氨酸(PS)与添加剂联合产生的效力和顺应性。
实施例
在公开研究中，按Wender Utah Rating等级量表(WURS)根据在学校成绩以及临床和生理上的试验选择受试者(实施例1至4)。
在短期补充的4，6和8周后，和较长期补充的2，4和6个月后评定。检查受试者以得到关于集中、注意、冲动、潜在的攻击性和多动的可测量的差异。在评估中，通过问讯表涉及受试者、父母和老师。
实施例1
在9周的时间里，每两天给予一名9岁女学生150mg磷脂酰丝氨酸以及100mg维生素E、维生素C、DHA和GLA的混合物。4周后已经可见积极的趋势；6周后可确定明显的积极效果。注意力、集中能力、记忆能力以及在校成绩有明显的提高。
实施例2
在7周的时间里，给予一名14岁男学生200mg磷脂酰丝氨酸，每日三次。在补充期结束时，观察到多动显著地减少；而且受试者报告一般感悟力有改善。
实施例3
在6个月的时间里，给予一名8岁男学生每日100mg磷脂酰丝氨酸。3个月后观察到一般健康状况的改善和情绪提高。注意力、集中能力和记忆能力以及在校成绩有明显的提高。
实施例4
8周内，每日给予一名11岁男学生400mg磷脂酰丝氨酸联合100mg含有DHA、金丝桃、维生素E和C的混合物。在短暂的补充期后，已经能够观察到情绪的明显改善和攻击行为减少，以及在校成绩提高。
Claims (27)
1.磷脂酰丝氨酸(PS)，溶血磷脂酰丝氨酸或/和其生理上可接受的盐，联合选自抗氧化剂、必需脂肪酸、矿物质、氨基酸、情绪提高剂、磷脂或/和其混合物的添加剂在制备用于治疗注意力缺乏综合症(ADHS)的制剂中的应用。
2.根据权利要求1所述的应用，其特征在于：磷脂酰丝氨酸，溶血磷脂酰丝氨酸或/和其生理上可接受的盐每日的给药剂量是20至1000mg。
3.根据权利要求2所述的应用，其特征在于：磷脂酰丝氨酸，溶血磷脂酰丝氨酸或/和其生理上可接受的盐每日的给药剂量是50至600mg。
4.根据权利要求1至3之一所述的应用，其特征在于：添加剂每日的给药剂量是1至10000mg。
5.根据权利要求4所述的应用，其特征在于：添加剂每日的给药剂量是5至5000mg。
6.根据权利要求4所述的应用，其特征在于：添加剂每日的给药剂量是50至1000mg。
7.根据权利要求1至6之一所述的应用，其特征在于：抗氧化剂选自生物类黄酮，维生素E，维生素C，α-硫辛酸或/和类胡罗卜素。
8.根据权利要求1至7之一所述的应用，其特征在于：必需脂肪酸选自ω-3-脂肪酸或/和ω-6-脂肪酸。
9.根据权利要求8所述的应用，其特征在于：必需脂肪酸为二十二碳六烯酸(DHA)或/和γ-亚麻酸(GLA)。
10.根据权利要求1至9之一所述的应用，其特征在于：矿物质选自镁或/和钙。
11.根据权利要求1至10之一所述的应用，其特征在于：氨基酸选自必需氨基酸或/和氨基酸衍生物。
12.根据权利要求11所述的应用，其特征在于：氨基酸衍生物为肌酸。
13.根据权利要求1至12之一所述的应用，其特征在于：情绪提高剂选自金丝桃提取物或/和Kava-Kava。
14.根据权利要求1至13之一所述的应用，其特征在于：磷脂选自磷脂酰胆碱、磷脂酸、磷脂酰乙醇胺或/和磷脂酰肌醇。
15.磷脂酰丝氨酸(PS)，溶血磷脂酰丝氨酸或/和其生理上可接受的盐在制备用于治疗注意力缺乏综合症(ADHS)的制剂中的应用，其特征在于：最多给药2个月，每日的给药剂量为150至600mg。
16.根据权利要求15所述的应用，其特征在于：每日的给药剂量为250至450mg。
17.磷脂酰丝氨酸(PS)，溶血磷脂酰丝氨酸或/和其生理上可接受的盐在制备用于治疗注意力缺乏综合症(ADHS)的制剂中的应用，其特征在于：在多于2个月的时间内给药，每日的给药剂量为50至150mg。
18.根据权利要求17所述的应用，其特征在于每日的给药剂量为100至150mg。
19.根据权利要求1至18之一所述的应用，其特征在于：给药至少7天。
20.根据权利要求1至19之一所述的应用，其特征在于：给药不长于6个月。
21.根据权利要求1至20之一所述的应用，其特征在于：治疗2至20岁的患者。
22.根据权利要求21所述的应用其特征在于：治疗3至10岁的患者。
23.根据权利要求1至22之一所述的应用，其特征在于：给予固体或/和液体制剂。
24.根据权利要求23所述的应用，其特征在于：制剂另外包括生理上可接受的或/和生理上有效的添加剂或/和制剂佐剂。
25.根据权利要求24所述的应用，其特征在于：生理上可接受的或/和生理上有效的添加剂选自抗氧化剂、糖、醇类、维生素、必需脂肪酸、微量元属、氨基酸、神经递质、微生态调节剂、磷脂、刺激物、着色剂或/和调味剂。
26.根据权利要求24所述的应用，其特征在于：制剂佐剂选自碳水化合物、SiO2、硬脂酸盐、增溶剂、调味剂、防腐剂和分离剂或/和增稠剂。
27.根据权利要求1至26之一所述的应用，其作为治疗剂、食品添加剂、功能食品或特殊食品。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10149108.5 | 2001-10-05 | ||
| DE10149108A DE10149108A1 (de) | 2001-10-05 | 2001-10-05 | Verwendung von Phosphatidylserin zur Behandlung des Aufmerksamkeits-Defizit-Syndroms (ADHS) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1638779A true CN1638779A (zh) | 2005-07-13 |
| CN100581551C CN100581551C (zh) | 2010-01-20 |
Family
ID=7701464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN02821564A Expired - Lifetime CN100581551C (zh) | 2001-10-05 | 2002-10-04 | 磷脂酰丝氨酸在治疗注意力缺乏综合症(adhs)中的应用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8129360B2 (zh) |
| EP (1) | EP1435971B1 (zh) |
| JP (1) | JP3924455B2 (zh) |
| KR (1) | KR100711276B1 (zh) |
| CN (1) | CN100581551C (zh) |
| AT (1) | ATE334685T1 (zh) |
| AU (1) | AU2002349326B2 (zh) |
| CA (1) | CA2462580C (zh) |
| DE (2) | DE10149108A1 (zh) |
| NZ (1) | NZ532148A (zh) |
| WO (1) | WO2003030914A1 (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105708843A (zh) * | 2016-04-07 | 2016-06-29 | 任永春 | 一种包含松果体素和磷脂酰丝氨酸的药物 |
| CN105816705A (zh) * | 2016-04-07 | 2016-08-03 | 赵卫军 | 一种包含玉米须和磷脂酰丝氨酸的药物及其制备方法 |
| CN110200289A (zh) * | 2019-05-30 | 2019-09-06 | 吉林农业大学 | 一种能够强化注意力的营养类食品添加剂配方 |
| CN112089056A (zh) * | 2020-09-22 | 2020-12-18 | 上海泓商生物科技有限公司 | 改善记忆力益生菌组合物 |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004038155A1 (de) * | 2004-08-06 | 2006-03-16 | Bioghurt Biogarde Gmbh & Co. Kg | Physiologisch verträgliche Zusammensetzung enthaltend alpha-Liponsäure, Kreatin und ein Phospholipid |
| DE102005003865A1 (de) * | 2005-01-27 | 2007-05-10 | Bioghurt Biogarde Gmbh & Co. Kg | Phosphatidylserin-basierte Zusammensetzung zur Steigerung der Gehirnfunktion |
| ITPD20050164A1 (it) * | 2005-05-30 | 2006-11-30 | Fidia Farmaceutici | Processo per la preparazione e l'isolamento di fosfatidi |
| DE102007042557A1 (de) | 2007-09-07 | 2009-03-19 | Membramed Gmbh | Neuartige Formulierung von Phospholipiden |
| US20100056484A1 (en) * | 2008-08-26 | 2010-03-04 | Scott Farese | Dietary supplemental composition effective for enhancing cognitive performance, elevating mood and reducing oxidative stress |
| CA2746509C (en) | 2008-12-19 | 2018-11-20 | Supernus Pharmaceuticals, Inc. | Use of molindone for the treatment of impulsive agression |
| JP6063377B2 (ja) | 2010-03-31 | 2017-01-18 | スパーナス ファーマシューティカルズ インコーポレイテッド | Ｃｎｓ化合物の安定化製剤 |
| CN101874630A (zh) * | 2010-05-24 | 2010-11-03 | 崔晓廷 | 一种增强记忆力认知力的脑保健品 |
| US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
| US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001026642A2 (en) * | 1999-10-08 | 2001-04-19 | Joyce Corinne Bechthold | Methods and compositions for treating neurobehavioral disorders |
| WO2001078704A2 (en) * | 2000-04-13 | 2001-10-25 | Evans William T | Gaba substrate and the use thereof for treating cognitive and emotional disorders |
| US7208180B2 (en) * | 2000-05-08 | 2007-04-24 | N.V. Nutricia | Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith |
| US6733797B1 (en) * | 2000-11-15 | 2004-05-11 | William K. Summers | Neuroceutical for improving memory and cognitive abilities |
| US6964969B2 (en) * | 2001-04-19 | 2005-11-15 | Mccleary Edward Larry | Composition and method for treating impaired or deteriorating neurological function |
| WO2003011873A2 (en) * | 2001-07-27 | 2003-02-13 | Neptune Technologies & Bioressources Inc. | Natural marine source phospholipids comprising flavonoids, polyunsaturated fatty acids and their applications |
-
2001
- 2001-10-05 DE DE10149108A patent/DE10149108A1/de not_active Withdrawn
- 2001-12-05 JP JP2001371173A patent/JP3924455B2/ja not_active Expired - Lifetime
-
2002
- 2002-10-04 AU AU2002349326A patent/AU2002349326B2/en not_active Ceased
- 2002-10-04 KR KR1020047004759A patent/KR100711276B1/ko active IP Right Grant
- 2002-10-04 WO PCT/EP2002/011124 patent/WO2003030914A1/de active IP Right Grant
- 2002-10-04 DE DE50207740T patent/DE50207740D1/de not_active Expired - Lifetime
- 2002-10-04 CN CN02821564A patent/CN100581551C/zh not_active Expired - Lifetime
- 2002-10-04 AT AT02781213T patent/ATE334685T1/de not_active IP Right Cessation
- 2002-10-04 NZ NZ532148A patent/NZ532148A/en not_active IP Right Cessation
- 2002-10-04 EP EP02781213A patent/EP1435971B1/de not_active Expired - Lifetime
- 2002-10-04 CA CA2462580A patent/CA2462580C/en not_active Expired - Lifetime
- 2002-10-04 US US10/491,636 patent/US8129360B2/en active Active
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105708843A (zh) * | 2016-04-07 | 2016-06-29 | 任永春 | 一种包含松果体素和磷脂酰丝氨酸的药物 |
| CN105816705A (zh) * | 2016-04-07 | 2016-08-03 | 赵卫军 | 一种包含玉米须和磷脂酰丝氨酸的药物及其制备方法 |
| CN110200289A (zh) * | 2019-05-30 | 2019-09-06 | 吉林农业大学 | 一种能够强化注意力的营养类食品添加剂配方 |
| CN112089056A (zh) * | 2020-09-22 | 2020-12-18 | 上海泓商生物科技有限公司 | 改善记忆力益生菌组合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| DE10149108A1 (de) | 2003-04-30 |
| NZ532148A (en) | 2007-06-29 |
| EP1435971A1 (de) | 2004-07-14 |
| WO2003030914A1 (de) | 2003-04-17 |
| US8129360B2 (en) | 2012-03-06 |
| KR20050033505A (ko) | 2005-04-12 |
| AU2002349326B2 (en) | 2007-05-17 |
| KR100711276B1 (ko) | 2007-04-25 |
| JP2003113086A (ja) | 2003-04-18 |
| CN100581551C (zh) | 2010-01-20 |
| DE50207740D1 (de) | 2006-09-14 |
| CA2462580C (en) | 2011-11-29 |
| CA2462580A1 (en) | 2003-04-17 |
| JP3924455B2 (ja) | 2007-06-06 |
| EP1435971B1 (de) | 2006-08-02 |
| ATE334685T1 (de) | 2006-08-15 |
| US20040235795A1 (en) | 2004-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100581551C (zh) | 磷脂酰丝氨酸在治疗注意力缺乏综合症(adhs)中的应用 | |
| KR100680121B1 (ko) | (리소-)포스파티딜세린을 포함하는 온혈동물에서 스트레스상태의 예방 및 치료용 제제 | |
| CN101248873A (zh) | 具有视力保护功能的饮用食品 | |
| US7879374B2 (en) | Composition including superoxide dismutase and prickly-pear cactus for minimizing and preventing hangovers | |
| US20050013884A1 (en) | Compositions and methods for treating heart disease | |
| EP4353263A1 (en) | Use of composition of alcohol and cooling agent in regulating sexual function, protecting cardiovascular and cerebrovascular system, promoting hepatocyte regeneration, fighting against tumor, and improving immunity and sleep quality | |
| CN101426490B (zh) | 包含α-酮戊二酸/盐的组合物及其用于调节肌肉性能的用途 | |
| DE102012008730A1 (de) | Orale Zusammensetzungen mit ungesättigten C18-Fettsäuren und ihre Verwendung | |
| EP3461479A1 (en) | Nutraceutical and pharmaceutical compositions, and uses thereof for preserving cognitive functions | |
| BG65399B1 (bg) | Билкова добавка за повишаване мускулната сила и издържливост на атлетите | |
| WO2006018294A1 (de) | Pharmazeutische zusammensetzung, umfassend galaktose, selen, vitamin e und/oder phosphatidylcholin und pharmazeutische verwendungen von galaktose | |
| JP5601747B2 (ja) | 疲労予防用内服用組成物及び疲労予防用内服用製剤 | |
| CN113854566A (zh) | 一种营养补充剂 | |
| CN102631503A (zh) | 一种抗疲劳中药组合物及其制备方法 | |
| KR101645589B1 (ko) | 데커신 및/또는 데커시놀 안젤레이트 또는 데커신 및/또는 데커시놀 안젤레이트를 유효성분으로 하는 당귀추출물, 쌀눈 추출물, 무말랭이 추출물을 유효성분으로 포함하는 알코올성 숙취 예방, 숙취 해소, 간장 보호 또는 피로 회복용 조성물 | |
| RU2160586C1 (ru) | Биологически активная добавка общеукрепляющего действия | |
| CN116019860B (zh) | 一种具有开窍醒神功效的复方精油及其制备方法与用途 | |
| CN108294138A (zh) | 一种既能提神醒脑又能缓解疲劳的饮料 | |
| RU2377009C1 (ru) | Биологически активная добавка, способствующая снижению массы тела | |
| CN115444067A (zh) | 一种巴戟天减压解郁口香糖 | |
| KR20220165292A (ko) | 감각 활성화제 조성물 및 이를 포함하는 감각 활성화제 | |
| Mutovkina et al. | Attenuation of effects of phenylethylamine on social and individual behaviour in mice by ethanol pretreatment | |
| CN115066237A (zh) | 用于治疗认知障碍的组合物 | |
| Foster et al. | THE CAUSES AND CONSEQUENCES OF VITAMIN B-3 DEFICIENCY: INSIGHTS FROM FIVE THOUSAND CASES | |
| LAILAR et al. | EFFECT OF NATURAL, HONEY (C) N E3 LOOD GLUCOSE LEVEL, OF ALLOXAN INDUCED DIA E3 ETIC RATS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: CARGILE FIBER CRIMP SCHEME GERMANY GMBH + CO. KG Free format text: FORMER OWNER: BIOGHURT BIOGARDE GMBH + CO KG Effective date: 20131014 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20131014 Address after: hamburg Patentee after: Cargill crimp German GmbH & Co.KG Address before: Germany Freising Patentee before: BIOGHURT BIOGARDE GmbH & Co.KG |
|
| ASS | Succession or assignment of patent right |
Owner name: NAGASE CHEMTEX CORP. Free format text: FORMER OWNER: CARGILE FIBER CRIMP SCHEME GERMANY GMBH + CO. KG Effective date: 20141202 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20141202 Address after: Osaka Patentee after: NAGASE CHEMTEX Corp. Address before: hamburg Patentee before: Cargill crimp German GmbH & Co.KG |
|
| CX01 | Expiry of patent term |
Granted publication date: 20100120 |
|
| CX01 | Expiry of patent term |